Journal of Pharmaceutical Research
DOI: 10.18579/jopcr/v17.3.ruby
Year: 2018, Volume: 17, Issue: 3, Pages: 27-36
Original Article
Ruby1, Giri Mrudula1,∗
1Department of Pharmacology, Krupanidhi College of Pharmacy, Carmelaram, Varthur Hobli, Bengaluru, Karnataka, India
*Corresponding Author
Email: [email protected]
Objectives: Allium cepa L. is an important dietary vegetable that has been used as a herbal medicine for centuries because of its potent antioxidant properties. Recently, amlodipine has been widely recognized for its potent antioxidant properties, attributed to its unique interactions with the membrane lipid bilayer. This mechanism may contribute to its cytoprotective action against cardiovascular disease. This study aimed to examine the synergistic protective effects of Allium cepa L. and amlodipine against isoproterenol-induced myocardial infarction in rats. Methods: Male Wistar albino rats were divided into six groups (n=6). Daily pre-treatment with Allium cepa L., amlodipine, and their combination for respectively period of 30 days. At the end of this period, rats were administered isoproterenol (85 mg/kg, s. c.) for two consecutive days to induce myocardial injury. After induction, the rats were anaesthetized with ketamine (22 mg/kg, i. m.) and sacrificed, and biochemical assays of heart tissues were performed. Findings: The results revealed the cardioprotective effect observed in the combination group showed significantly reduced isoproterenol-induced elevations in diagnostic marker enzyme levels and almost restored normal levels. This combination demonstrated a synergistic antioxidant effect by inhibiting the induction of lipid peroxidation and increasing superoxide dismutase activity. Histopathological observations supported these biochemical results. Novelty: Allium cepa L. and amlodipine can be used in combination as cardioprotective agents against myocardial infarction.
Keywords: Allium cepa L, Amlodipine, Isoproterenol, Myocardial Infarction
© 2018 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Subscribe now for latest articles and news.